|12/4/10||BioCryst Pharma Reports New Data From Phase 2 Forodesine Study (Penny Stock DD)|
Date: 4 December 2010 (RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX) announced the presentation of new data that confirms forodesine's clinical activity in the treatment of chronic lymphocytic leukemia, or CLL, at the 52nd Annual American Society of Hematology Meeting & Exposition being held in Orlando, Florida. In the Phase [...]
|9/16/10||Day Trader's Alert: BCRX, INCY, CLU (Stock Wizard)|
Shares of BioCryst Pharmaceuticals, Inc. (NasdaqGM: BCRX) surged as much as 3% after it announced today positive top-line results from its randomized, double-blind, multi-center, placebo-controlled Phase 2 study designed to evaluate the urate-lowering activity and safety of several doses of BCX4208 alone and in combination with selected doses of allopurinol administered once-daily. Shares of Incyte Corporation (NASDAQ: INCY) soared as much as 2% after it said that the results from...
|2/4/10||Swine Flu Antiviral Helps BioCryst Crush Estimates in Q4 (BCRX, NVS, SNY, RHHBY, SVA, APT, GNBT, ... (tickerspy.com)|
While select swine flu players have seen their pops and drops, BioCryst Pharmaceuticals (BCRX) may have emerged as the small-cap champion of the 2009 pandemic. Birmingham, Alabama-based biopharmaceutical small-cap BioCryst Pharmaceuticals is shooting higher today after topping fourth-quarter EPS consensus by 26 cents. The company earned $15.2 million or 35 cents a share in the [...]
|11/9/09||Top H1N1 Drug Companies Performance: Effective Marketing (Shocked Investor)|
We track the companies that make H1N1-related products on this site. The top performer year-to-date is BCRX (Biocryst), with a staggering return of 723%, followed by SVA (Sinovac), +492%. At least here in Canada, the few H1N1 deaths have been well publicized, instilling fear and near-panic in the population. Citizens were routinely lining-up for many hours to get their H1N1 flu-shots. Although that there are now shortages of the vaccine, blamed on various reasons, experts are already saying...
|11/5/09||The $2000 Swine Flu Drug (tickerspy.com)|
The peramivir pricing speculation is over, and the first order has been shipped. The U.S. FDA issued BioCryst Pharmaceuticals (BCRX) emergency use authorization for its swine flu antiviral in October, but at that point a price had not been settled. In an interview with CNBC, CEO Jon Stonehouse declined to comment on his negotiations with [...]
|9/22/09||BioCryst Steps Closer to Emergency Application (tickerspy.com)|
Peramivir is one step closer to hitting the market, but still no emergency use contract. Birmingham, Alabama-based BioCryst Pharmaceuticals' (BCRX) late-stage Tamiflu rival, peramivir, earned the company a request for proposal (RFP) from the U.S. Department of Health & Human Services (HHS). According to Monday's press release, the government could order between 1,000 and 40,000 [...]
|9/21/09||H1N1 BioCryst (BCRX) Alert: Stock May Soar or Crash, Straddles (Shocked Investor)|
BioCryst Pharmaceuticals today announced that it received an RFP (request for proposal) from the U.S. Department of Health & Human Services (HHS) for the supply of Peramivir for the treatment of critically ill influenza patients under Emergency Use Authorization (EUA). Perimavir is in late-stage trials and the FDA is considering a "pre-emergency use authorization review". The company is preparing a response. The RFP indicates that the minimum and maximum order quantities to be ordered by the...
|9/15/09||Stock To Watch – BioCryst (Navivest Stocks and Options Blog)|
Shares of pharmaceutical company BioCryst (BCRX) are up $1.40 or 13.05% to $12.13, on a report from the company, that it has signed three marketing deals for territories outside the U.S, for its antiviral peramivir drug for the flu. The marketing partners will exclusively represent the drug in their respective markets for stockpiling opportunities, as [...]
|9/14/09||BioCryst takes on Tamiflu (tickerspy.com)|
Peramivir could be the next swine flu-fighting one-dose wonder. BioCryst Pharmaceuticals (NADSAQ: BCRX) has been one of the hottest swine flu plays on the Street, spiking by 700% over the last six months. Moves in the stock have been closely tied to the company's peramivir drug, which according to a recent study is as effective [...]
|8/24/09||Trading results 8/24/09 (Robert Weinstein Trading Blog)|
Today started out pretty good and stayed that way. I would have liked to have made a larger gain with BCRX as I ended up taking a stop loss to protect the small gains I had and not allow a winner to turn into a loser. BCRX actually hit the profit target by the book [...]
|7/30/09||The Swine Flu Play (Contrarian Profits)|
In June, the World Health Organization (WHO) alerted the public that a worldwide pandemic of swine flu (H1N1) was sweeping the globe. Health officials at the Centers for Disease Control and Prevention (CDC) have stated that the swine flu virus could infect up to 40% of Americans over the next couple of years. At last count, [...]
|7/21/09||Mini Flu Basket (All Allan)|
At the top of my list of Flu stocks is NNVC , a topic already well covered in prior blogs. We like NNVC for a host of reasons, Avian , Swine and other forms of Flu among them. For today's blog, I want to focus on three low priced stocks that are running in the atmosphere of a global flu pandemic, BCRX , HEB and NVAX . BCRX - Hourly HEB - Hourly NVAX - Hourly The only feature I considered today before buying these three stocks is that they were all in Wave...